MENU

05.01.19

Young Blood Plasma for Parkinson's Disease


Results of a clinical trial that administered blood plasma from donors, age 18 to 25 years, into individuals with Parkinson's disease resulted in significant improvements in neurologic assessments.

After 3 months, patients showed improvements in motor examinations (19.2%); mentation, behavior, and mood (12.9%); activities of daily living (7.9%); and complications from therapy (50%). Symptoms including dyskinesia and changes in facial expression, speech, handwriting, rigidity, and falling all showed improvement directly attributable to the young plasma. 

The randomized, double-blind, placebo-controlled trial evaluated the efficacy of the plasma (NuPlasma young Fresh Frozen Plasma; NuPlasma, San Marcos, TX) in 19 patients (9 were given young plasma; 10 were given placebo). Patients were intravenously administered 25 mL/kg of the plasma in 2 doses over 3 days.The investigation continued to the point at which the plasma was no longer in circulation, yet continued to show a residual benefit.

Clinical Trial of Phosphodiesterase Inhibitor Begins for Treatment of Early Alzheimer's Disease

Previous News Article

Tofersen for Treatment of Familial Amyotrophic Lateral Sclerosis

Next News Article
This Month's Issue
Case Report: Seizure, Fever, Hallucinations, & Vision Loss

Elizabeth Carroll, MD; Asya I. Wallach, MD; Arielle Kurzweil, MD; Steven Frucht, MD; Thomas Berk, MD; Michael Boffa, MD; and Ilya Kister, MD

Neuroimaging and Alzheimer’s Disease

Mary Ellen Koran, MD, PhD

MS Minute: Oral Therapies for MS

Neeta Garg, MD; Micheline McCarthy, MD, PhD; and Ameeta Karmarkar, MD